Only one traditional preclinical biotech—Metagenomi—went public last year, compared to around a quarter of the biotechs that IPOed in 2020 and 2021, according to Surti. About two-thirds of the ...

Ascentage sold 7,325,000 American Depositary shares at $17.25 each. Credit: Andrey Zhuravlev via Getty Images. China-based biotech Ascentage Pharma has raised $126m in a US initial public offering ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...